Literature DB >> 19730984

In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.

Hasibe Artac1, Reyhan Kara, Ismail Reisli.   

Abstract

Although the presence of physiologic anti-CD95 (Fas, APO-1) autoantibodies in intravenous immunoglobulin (IVIG) preparations is known, the effects of these antibodies in patients with common variable immunodeficiency are unclear (CVID). The aim of the study was to assess the effects of IVIG in Fas expression, activation markers and the subsets of T cells in patients with CVID. We studied 15 cases with CVID and 10 healthy controls with no signs of immunodeficiency. The Fas expression of T cells, activation markers (CD25, CD69 and HLA-DR) and T-cell subsets were analyzed by four-color flow cytometry. We found that the Fas expression of CD3+ T cells in patients was significantly higher than in controls. In addition, there was a significant increase in the Fas expression of CD3+ T cells and CD4+ T cells, and the CD25 expression of CD3+ and CD4+ T cells after IVIG supplementation (P < 0.05). The CD69 and HLA-DR expressions of T cells and CD8+ T cells were not affected by IVIG infusion. Our observation showed that IVIG replacement causes an increase in the Fas and CD25 expressions in patients with CVID. These data suggest that the Fas protein may have an important role in the effects of IVIG for the control of autoimmunity in patients with CVID, as well as in the generation of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19730984     DOI: 10.1007/s10238-009-0061-1

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  29 in total

1.  Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis.

Authors:  O Aktas; S Waiczies; U Grieger; U Wendling; R Zschenderlein; F Zipp
Journal:  J Neuroimmunol       Date:  2001-03-01       Impact factor: 3.478

Review 2.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

3.  Comparative analysis of whole blood lysis methods for flow cytometry.

Authors:  X Bossuyt; G E Marti; T A Fleisher
Journal:  Cytometry       Date:  1997-06-15

Review 4.  Mechanisms of action of intravenous immune globulin in immune-mediated diseases.

Authors:  L Mouthon; S V Kaveri; S H Spalter; S Lacroix-Desmazes; C Lefranc; R Desai; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

5.  In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

Authors:  W A Sewell; M E North; R Cambronero; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

Review 7.  Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.

Authors:  Lars E French
Journal:  Allergol Int       Date:  2006-03       Impact factor: 5.836

8.  Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.

Authors:  Frank Altznauer; Stephan von Gunten; Peter Späth; Hans-Uwe Simon
Journal:  J Allergy Clin Immunol       Date:  2003-12       Impact factor: 10.793

9.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

Authors:  N K Prasad; G Papoff; A Zeuner; E Bonnin; M D Kazatchkine; G Ruberti; S V Kaveri
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  4 in total

Review 1.  Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.

Authors:  S V Kaveri; M S Maddur; P Hegde; S Lacroix-Desmazes; J Bayry
Journal:  Clin Exp Immunol       Date:  2011-06       Impact factor: 4.330

2.  Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders.

Authors:  Pauline A van Schouwenburg; Emma E Davenport; Anne-Kathrin Kienzler; Ishita Marwah; Benjamin Wright; Mary Lucas; Tomas Malinauskas; Hilary C Martin; Helen E Lockstone; Jean-Baptiste Cazier; Helen M Chapel; Julian C Knight; Smita Y Patel
Journal:  Clin Immunol       Date:  2015-06-26       Impact factor: 3.969

Review 3.  Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects.

Authors:  Andrea Matucci; Enrico Maggi; Alessandra Vultaggio
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

4.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.